SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
REDWOOD CITY, Calif., Feb. 05, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that Denny Lanfear, President and Chief Executive Officer, will be a featured speaker at the 4th Annual Bloomberg Intelligence Healthcare Event.
The discussion will be held on Friday, February 12 starting at 2:00 pm ET in New York City. Information regarding the event is available at www.bloomberglp.com/healthcareevent2016.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.
INVESTOR AND MEDIA CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
